---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012856"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:03:52.621135+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q1 revenue $1.4M, net loss widens; CFO and Chairman transitions announced

## Summary
- Q1 2022 total revenue $1.4M vs $1.1M YoY; DetermaRx revenue $1.0M.
- Net loss $10.3M ($0.11 per share) vs net loss $3.9M ($0.05) a year ago.
- Cash, equivalents & marketable securities $22.7M as of March 31, 2022.
- Chairman Cavan Redmond not standing for reelection; Andrew Arno appointed Chairman effective May 6.
- CFO Mitchell Levine to transition to Corporate Development Officer; Anish John named Interim CFO.

## SEC filing metadata
- accession: 0001493152-22-012856
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012856
- JSON: https://secwatch.observer/filing/0001493152-22-012856.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012856.txt

## Key facts
- Executive change
  Mitchell Levine changed role as Chief Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: will no longer serve
  - Role: Chief Financial Officer
  source text: Mitchell Levine, our Chief Financial Officer since 2017, will no longer serve in that capacity as of June 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm
- Executive change
  Cavan Redmond changed role as Chairman of the Board at Insight Molecular Diagnostics Inc..
  - Action: stepped down
  - Role: Chairman of the Board
  source text: Mr. Redmond has stepped down as Chairman of the Board, and that the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm
- Executive change
  Andrew Arno was appointed as Chairman of the Board at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: the Board has appointed Andrew Arno as Chairman of the Board effective May 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm
- Executive change
  Anish John was appointed as Senior Vice President, Finance, and Interim Chief Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Senior Vice President, Finance, and Interim Chief Financial Officer
  source text: Anish John, our Vice President, Operations – Transplant, has been appointed Senior Vice President, Finance, and Interim Chief Financial Officer effective June 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222012856/0001493152-22-012856-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.